KNX101
Acute and chronic pain
Preclinical/IND‑enablingActive
Key Facts
Indication
Acute and chronic pain
Phase
Preclinical/IND‑enabling
Status
Active
Company
About Kinoxis Therapeutics
Australian biotech leveraging ALOX15 inhibition for CNS agitation, pain, and substance‑use disorders.
View full company profileTherapeutic Areas
Other Acute and chronic pain Drugs
| Drug | Company | Phase |
|---|---|---|
| NTM-006 | Neumentum | Phase 2 |
| MAX-001 | Maxona Pharmaceuticals | Phase 2 |
| Pain Therapy Portfolio | Molteni Farmaceutici | Approved |